Some Love for Express Scripts
By Paul Price
On March 14, a director of ESRX bought 5,000 shares in the company for $297,925 ($59.585 /share).
Value Line reviewed ESRX in its new March 22 issue. According to Value Line, Express Scripts is performing well. Industry conditions remain favorable and merger benefits from the April 2012 Medco acquisition are still building up.
The company has a good balance sheet. GAAP EPS, which dipped to $1.79 last year, are expected to reach $2.80 in 2013. Value Line sees $5.30 per share in profits over the next 3 – 5 years. Its long term target price projection centers on $117.50. That's almost double the March 18 closing quote of $59.54.
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.